āĻšā§āĻŽINO âĸ BMV
add
Inovio Pharmaceuticals Inc
⧍ā§Ŧ.ā§Ļā§Ļ$
ā§Ž āĻā§āϞ, ā§Š:ā§Ļā§Ļ:ā§§ā§Ļ PM GMT -ā§Ŧ · MXN · BMV · āĻĄāĻŋāϏāĻā§āϞā§āĻŽāĻžāϰ
āĻāĻžāϞ āĻļā§āώ āϝ⧠āĻĻāĻžāĻŽā§ āĻāĻŋāϞ
⧍ā§Ģ.ā§Ļā§Ļ$
āϏāĻžāϰāĻž āĻĻāĻŋāύā§āϰ āĻā§āϰā§āĻĄāĻŋāĻā§ā§ āϏā§āĻāĻā§āϰ āĻĻāĻžāĻŽā§āϰ āĻāĻ āĻž āύāĻžāĻŽāĻžāϰ āϰā§āĻā§āĻ
⧍ā§Ŧ.ā§Ļā§Ļ$ - ā§¨ā§Ž.ā§Ļā§Ļ$
āϏāĻžāϰāĻž āĻŦāĻāϰā§āϰ āϰā§āĻā§āĻ
⧍ā§Ģ.ā§Ļā§Ļ$ - ⧍⧍ā§Ē.ā§Šā§Ļ$
āĻŽāĻžāϰā§āĻā§āĻ āĻā§āϝāĻžāĻĒ
ā§Ŧ.ā§Žā§ŠÂ āĻā§ USD
āĻāĻĄāĻŧ āĻāϞāĻŋāĻāĻŽ
⧧⧝⧍.ā§Ļā§Ļ
P/E āĻ
āύā§āĻĒāĻžāϤ
-
āϞāĻā§āϝāĻžāĻāĻļ āĻĒā§āϰāĻĻāĻžāύ
-
āĻĒā§āϰāĻžāĻāĻŽāĻžāϰāĻŋ āĻāĻā§āϏāĻā§āĻā§āĻ
NASDAQ
āĻāĻŦāϰ⧠āϰā§ā§āĻā§
āĻĢāĻžāĻāύāĻžāύā§āϏāĻŋā§āĻžāϞ āĻĒāĻžāϰāĻĢāϰā§āĻŽā§āϝāĻžāύā§āϏ
āĻā§ā§āϰ āϏā§āĻā§āĻāĻŽā§āύā§āĻ
āĻāĻĒāĻžāϰā§āĻāύ
āύā§āĻ āĻāύāĻāĻžāĻŽ
(USD) | āĻŽāĻžāϰā§āĻ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻāĻĒāĻžāϰā§āĻāύ | ā§Ŧā§Ģ.ā§Šā§Ē āĻšāĻž | â |
āĻŦā§āϝāĻŦāϏāĻž āĻāĻžāϞāĻžāύā§āϰ āĻāϰāĻ | ⧝ā§Ļ.⧍ā§Ģ āϞāĻž | -ā§§ā§Ē.ā§Ŧā§Š% |
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§§.⧝ā§Â āĻā§ | ā§Šā§Ģ.ā§Šā§Ŧ% |
āύā§āĻ āĻĒā§āϰāĻĢāĻŋāĻ āĻŽāĻžāϰā§āĻāĻŋāύ | -ā§Šā§Ļ.ā§§ā§Ē āĻšāĻž | â |
āĻļā§ā§āĻžāϰ āĻĒā§āϰāϤāĻŋ āĻāĻĒāĻžāϰā§āĻāύ | -ā§Ļ.ā§Ģā§§ | ā§Ŧā§§.ā§Ļā§% |
EBITDA | -⧍.ā§Ēā§Â āĻā§ | ⧍ā§Ļ.ā§Ģā§Ē% |
āĻĒā§āϰāϝā§āĻā§āϝ āĻā§āϝāĻžāĻā§āϏā§āϰ āĻšāĻžāϰ | â | â |
āĻŦā§āϝāĻžāϞā§āύā§āϏ āĻļāĻŋāĻ
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(USD) | āĻŽāĻžāϰā§āĻ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āĻā§āϝāĻžāĻļ āĻ āĻāĻŽ āϏāĻŽā§ā§āϰ āĻŦāĻŋāύāĻŋā§ā§āĻ | ā§Ŧ.ā§Žā§Ē āĻā§ | -ā§Šā§Ģ.⧍ā§% |
āĻŽā§āĻ āϏāĻŽā§āĻĒāĻĻ | ā§Ž.ā§ā§ŠÂ āĻā§ | -ā§Šā§¨.ā§Ēā§§% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Š.ā§Ŧā§Ļ āĻā§ | ā§Š.ā§Žā§¯% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§Ģ.ā§§ā§ŠÂ āĻā§ | â |
āĻāĻāĻāϏā§āĻā§āϝāĻžāύā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāϰ | ā§Š.ā§Ŧā§Â āĻā§ | â |
āĻĒā§āϰāĻžāĻāϏ āĻā§ āĻŦā§āĻ āϰā§āĻļāĻŋāĻ | ā§§ā§.ā§Žā§Ŧ | â |
āϏāĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | -ā§Ŧ⧍.ā§Ēā§Ž% | â |
āĻŽā§āϞāϧāύ āĻĨā§āĻā§ āĻā§ | -ā§Žā§.ā§Ŧā§Ŧ% | â |
āĻā§āϝāĻžāĻļ āĻĢā§āϞā§
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ
(USD) | āĻŽāĻžāϰā§āĻ ā§¨ā§Ļ⧍ā§Ģinfo | Y/Y āĻĒāϰāĻŋāĻŦāϰā§āϤāύ |
---|---|---|
āύā§āĻ āĻāύāĻāĻžāĻŽ | -ā§§.⧝ā§Â āĻā§ | ā§Šā§Ģ.ā§Šā§Ŧ% |
āĻ
āĻĒāĻžāϰā§āĻļāύ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āϝāĻžāĻļ | -⧍.ā§Ŧā§¯Â āĻā§ | ā§Ŧ.ā§Ģā§Ŧ% |
āĻŦāĻŋāύāĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | -ā§Ģā§§.ā§ā§Ģ āĻšāĻž | -ā§§ā§Ļā§Ļ.ā§§ā§§% |
āĻĢāĻžāĻāύā§āϝāĻžāύā§āϏāĻŋāĻ āĻĨā§āĻā§ āĻĒā§āϰāĻžāĻĒā§āϤ āĻā§āϝāĻžāĻļ | ā§§ā§Ļ.ā§¨ā§ŽÂ āϞāĻž | ā§§ā§Ļ⧝.ā§Ļā§Ģ% |
āύāĻāĻĻā§ āĻŽā§āĻ āĻĒāϰāĻŋāĻŦāϰā§āϤāύ | -⧍.ā§Ģā§¯Â āĻā§ | -ā§Ģā§Žā§¯.ā§Ēā§% |
āĻĢā§āϰāĻŋ āĻā§āϝāĻžāĻļ āĻĢā§āϞ⧠| -⧍.ā§§ā§Ģ āĻā§ | -⧍ā§Ŧ.ā§ā§Ģ% |
āϏāĻŽā§āĻĒāϰā§āĻā§
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
āϏāĻŋāĻāĻ
āĻā§ā§āĻŦāϏāĻžāĻāĻ
āĻāϰā§āĻŽāĻāĻžāϰā§
ā§§ā§Šā§Ē